An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. Researchers report that one dose of their vaccine candidate elicited large increases in RSV-neutralizing antibodies that were sustained for several months.
New vaccine against Respiratory Syncytial Virus (RSV) elicits strong immune response
Related Posts
Propecia 2025-2026
September 10, 2025Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024
About admin
Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge.
Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →